In this study, we demonstrated the potential of propranolol as a potent immune modulatory agent that can enhance the therapeutic efficacy of anti-CTLA4 checkpoint inhibitor therapy in STS using a murine fibrosarcoma model. This evidence concerns the gene CTLA4 and telomere syndrome.